Obstetric and neo-natal outcomes of ICSI cycles using pentoxifylline to identify viable spermatozoa in patients with immotile spermatozoa.
Pentoxifylline (PF) represents an effective tool in stimulating motility and identifying viable spermatozoa in intracytoplasmic sperm injection (ICSI) patients presenting exclusively with immotile spermatozoa. However, its use is not universally accepted for its possible detrimental effects on oocytes, embryos or newborns. To evaluate whether PF use may affect obstetrical/neo-natal outcomes, 102 patients achieving a clinical pregnancy after a PF-ICSI in four IVF units in Spain and Italy were followed up after delivery. Neo-natal malformations were classified according to the World Health Organization International Classification of Diseases (ICD-10, range Q00-Q99). Malformation rate was compared with data published by other groups regarding children conceived by conventional IVF or ICSI reporting a 5.3% and 4.4% frequency of ICD-10 codes, respectively. Of 134 clinical pregnancies, 122 babies (82 singletons and 40 twins) were registered. Among singletons, the rates of low birthweight (≤2500 g) and preterm birth (<37 weeks) were 6.1% and12%, respectively. Regarding malformation rate per live births, 4/122 (3.3%, 95% confidence interval: 0.9-8.2%) babies with ICD-10 malformations were recorded. This is the first report on neo-natal outcomes deriving from PF-ICSI. Although based on a limited cohort, results do not suggest an increase of adverse outcomes, including malformation rates, following this procedure.
Unidad Reproducción, UGC Laboratorio Clínico y UGC Obstetricia y Ginecología, CHU Granada, Instituto de Investigación Biosanitaria de Granada (IIBG), Granada, Spain.
Purificación
P
Navas
Infertility Unit, Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Alessio
A
Paffoni
Obstetrics and Gynaecology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Giulia
G
Intra
Clínica MasVida y CEIFER Biobanco, Sevilla, Spain.
Antonio
A
González-Utor
Unidad Reproducción, UGC Laboratorio Clínico y UGC Obstetricia y Ginecología, CHU Granada, Instituto de Investigación Biosanitaria de Granada (IIBG), Granada, Spain.
Ana
A
Clavero
Unidad Reproducción, UGC Laboratorio Clínico y UGC Obstetricia y Ginecología, CHU Granada, Instituto de Investigación Biosanitaria de Granada (IIBG), Granada, Spain.
Maria Carmen
MC
Gonzalvo
Clínica MasVida y CEIFER Biobanco, Sevilla, Spain.
Rocío
R
Díaz
Clínica MasVida y CEIFER Biobanco, Sevilla, Spain.
Rocío
R
Peña
Infertility Unit, Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Liliana
L
Restelli
Infertility Unit, Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Edgardo
E
Somigliana
Division of Genetics and Cell Biology, Reproductive Sciences Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Enrico
E
Papaleo
Unidad Reproducción, UGC Laboratorio Clínico y UGC Obstetricia y Ginecología, CHU Granada, Instituto de Investigación Biosanitaria de Granada (IIBG), Granada, Spain; Clínica MasVida y CEIFER Biobanco, Sevilla, Spain.
Jose A
JA
Castilla
Division of Genetics and Cell Biology, Reproductive Sciences Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: vigano.paola@hsr.it.
Paola
P
Viganò
D000328:Adult; D005260:Female; D006801:Humans; D007248:Infertility, Male; D008297:Male; D010431:Pentoxifylline / Q000009:adverse effects* / Q000494:pharmacology; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D055101:Semen Analysis / Q000379:methods*; D013030:Spain; D020554:Sperm Injections, Intracytoplasmic; D013081:Sperm Motility / Q000187:drug effects*
D010431:Pentoxifylline
ICSI; IVF; Low birthweight; Malformations; Pentoxifylline; Preterm birth